Skip to main content

Table 1 Demographics and baseline characteristics of the cohort of anemic chronic kidney disease participants treated with usual or high-dose ESA

From: Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors

Variable High-dose ESA
(≥1 mcg/kg/wk of
darbepoetin-α)
(n = 11)
Usual-dose ESA
(< 1 mcg/kg/wk of
darbepoetin-α)
(n = 21)
P-value
Age 71.1 ± 11.2 67.4 ± 10.2 0.38
Primary Cause of Kidney Disease (%)    0.13
   Diabetes 3 (27.3%) 10 (47.6%)  
   Hypertension 3 (27.3%) 6 (28.6%)  
   Glomerulonephritis 0 (0.0%) 2 (9.5%)  
   Unknown 3 (27.3%) 0 (0.0%)  
   Other 2 (18.2%) 3 (14.3%)  
Male Sex 1 (9%) 8 (38.1%) 0.11
Race (%)    0.71
   Black 5 (45.5%) 12 (57.1%)  
   White 6 (54.6%) 9 (42.9%)  
Weight (kg) 80.6 ± 29.6 92.0 ± 21.8 0.28
Blood Pressure (mmHg)    
   Systolic 127.0 ± 11.0 130.0 ± 16.2 0.54
   Diastolic 67.2 ± 8.3 68.8 ± 13.1 0.72
Heart rate (beats/min) 80.4 ± 19.4 74.3 ± 11.2 0.36
Baseline Comorbidities (%)    
   Diabetes, non insulin requiring 3 (27.3%) 7 (33.3%) 0.99
   Diabetes, insulin requiring 5 (45.5%) 9 (42.9%) 0.99
   Cerebrovascular accident 0 (0.0%) 3 (14.3%) 0.53
   Hypertension 11 (100.0%) 21 (100.0%) 0.99
   Hyperparathyroidism 7 (63.6%) 15 (71.4%) 0.70
   Congestive heart failure 2 (18.2%) 1 (4.8%) 0.27
   Cancer 0 (0.0%) 2 (9.5%) 0.53
   Coronary artery disease 3 (27.3%) 6 (28.6%) 0.99
Darbepoetin-α dose (3-month average) 94.1 mcg/week (1.4 mcg/kg/week) 49.7 mcg/week
(0.5 mcg/kg/week)
0.001
Baseline Medications (%)    
   Vitamin D 7 (63.6%) 14 (66.7%) 0.99
   HMG-CoA reductase inhibitor 7 (63.6%) 10 (47.6%) 0.47
   Oral Iron 7 (63.6%) 17 (81.0%) 0.40
   Intravenous Iron 1 (9.1%) 1 (4.8%) 0.99
Non-calcium containing phosphorus
binder
0 (0.0%) 1 (4.8%) 0.99
Calcium-containing phosphorus
binder
2 (18.2%) 3 (14.3%) 0.99
   Coumadin 2 (18.2%) 1 (4.8%) 0.27
   Aspirin 6 (54.6%) 14 (66.7%) 0.70
   ACE/ARB 7 (63.6%) 16 (76.2%) 0.68
   Alpha antagonist 0 (0.0%) 4 (19.1%) 0.27
   Beta blocker 6 (54.6%) 13 (61.9%) 0.72
   Calcium channel blocker 5 (45.5%) 10 (47.6%) 0.99
   Nitroglycerin 1 (9.1%) 3 (14.3%) 0.99
Hematology Laboratory Values    
   3-month average hemoglobin (g/dl) 10.4 ± 0.7 11.5 ± 0.8 0.0005
   Hemoglobin at enrollment (g/dl) 10.8 ± 1.0 12.3 ± 0.9 0.0004
   Serum Iron (mcg/dl) 75.9 ± 31.6 78.1 ± 21.8 0.94
   Serum Ferritin (ng/ml, median, IQR) 343.0 (224.0, 673.0) 353.0 (314.0, 493.0) 0.93*
   Transferrin saturation, % 28.9 ± 10.3 32.1 ± 8.6 0.59
Chemistry Laboratory Values    
   Serum blood urea nitrogen (mg/dl) 58.3 ± 24.8 54.6 ± 14.8 0.66
   Serum creatinine (mg/dl) 2.6 ± 1.2 2.7 ± 1.1 0.88
   MDRD GFR (ml/min per 1.73 m2) 25.9 ± 15.1 25.9 ± 9.3 0.99
   Serum glucose (mg/dl, median, IQR) 109.0 (88.0, 134.0) 113.0 (89.0, 154.5) 0.47*
   Serum albumin (mg/dl) 4.0 ± 0.4 3.9 ± 0.3 0.38
   Serum phosphorus (mg/dl) 4.5 ± 1.0 4.1 ± 0.6 0.22
   Serum PTH (pg ml-1, median, IQR) 148.5 (39.0, 208.0) 99.0 (52.0, 167.0) 0.59*
  1. *nonparametric test used